CBD Effective in Treating Pulmonary Hypertension
Lexaria Bioscience recently conducted a trial for their proprietary DehydraTECH-CBD formula and found that it effectively treats pulmonary hypertension.
Namely, DehydraTECH-CBD is a cannabidiol-based molecule manufactured by the company’s DehydraTECH™ technology.
As a result, Lexaria Bioscience products boost the absorption of oil-soluble drugs through the blood-brain barrier, making substances more effective in smaller doses.
Pulmonary hypertension, or PH, is a severe condition that affects a person’s ability to breathe and leads to heart failure and even death. In one of the subtypes, the blood vessels in the lungs are either damaged or blocked, which causes so-called pulmonary arterial hypertension (PAH).
Sixteen young and healthy individuals (18–35) participated in the experiment. They were each placed in a low-oxygen environment containing merely 12% oxygen instead of the standard 21%.
These conditions cause pulmonary vasoconstriction — a state where the lungs’ arteries constrict, thus mimicking the pathology of pulmonary hypertension.
To reveal the effectiveness of CBD, the participants were given either 300mg of DehydraTECH-CBD or a placebo half an hour before being exposed to low oxygen.
Interestingly, the results were positive for those who took CBD instead of the placebo. For instance, in male participants, arterial blood pressure was down by 41% during treatment.
If everything goes well, this CBD-based medication could be used to treat several hypoxia-inducing conditions, ranging from high altitude exposure sickness to severe lung disease.